Cargando…

Targeting oncogenic KRAS in non-small cell lung cancer with EGFR aptamer-conjugated multifunctional RNA nanoparticles

KRAS mutations are one of the most common oncogenic driver mutations in human cancers, including non-small cell lung cancer (NSCLC), and have established roles in cancer pathogenesis and therapeutic resistance. The development of effective inhibitors of mutant KRAS represents a significant challenge...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Linlin, Li, Zhefeng, Binzel, Daniel W., Guo, Peixuan, Williams, Terence M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10448464/ https://www.ncbi.nlm.nih.gov/pubmed/37637206 http://dx.doi.org/10.1016/j.omtn.2023.07.027

Ejemplares similares

Insights into EGFR Mutations and Oncogenic KRAS Mutations in Non-Small-Cell Lung Cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Eliminating blood oncogenic exosomes into the small intestine with aptamer-functionalized nanoparticles
por: Xie, Xiaodong, et al.
Publicado: (2019)

Targeting Oncogenic KRAS in Non-Small-Cell Lung Cancer
por: Sunaga, Noriaki, et al.
Publicado: (2021)

Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides
por: Wang, Dali, et al.
Publicado: (2022)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma
por: Unni, Arun M, et al.
Publicado: (2015)

Publisher Correction: Eliminating blood oncogenic exosomes into the small intestine with aptamer-functionalized nanoparticles
por: Xie, Xiaodong, et al.
Publicado: (2020)

Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosis
por: Liu, Xinquan, et al.
Publicado: (2019)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

Aptamer-Conjugated Multifunctional Polymeric Nanoparticles as Cancer-Targeted, MRI-Ultrasensitive Drug Delivery Systems for Treatment of Castration-Resistant Prostate Cancer
por: Fang, Youqiang, et al.
Publicado: (2020)

KIF5B-RET Fusion gene may coincide oncogenic mutations of EGFR or KRAS gene in lung adenocarcinomas
por: Kim, Jeong-Oh, et al.
Publicado: (2015)

EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation
por: Antonicelli, Alberto, et al.
Publicado: (2013)

Nanoparticle Orientation to Control RNA Loading and Ligand Display on Extracellular Vesicles for Cancer Regression
por: Pi, Fengmei, et al.
Publicado: (2017)

Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma
por: Blons, Hélène, et al.
Publicado: (2008)

PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup
por: Wang, Lei, et al.
Publicado: (2014)

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
por: Román, Marta, et al.
Publicado: (2018)

KRAS oncogene may be another target conquered in non‐small cell lung cancer (NSCLC)
por: Chen, Hanxiao, et al.
Publicado: (2020)

Targeting lung cancer with clinically relevant EGFR mutations using anti-EGFR RNA aptamer
por: Thomas, Brian J., et al.
Publicado: (2023)

Glycated albumin precipitation using aptamer conjugated magnetic nanoparticles
por: Fayazi, R., et al.
Publicado: (2020)

Aptamer-conjugated gold nanoparticles and their diagnostic and therapeutic roles in cancer
por: Deng, Guozhen, et al.
Publicado: (2023)

Entropy-Driven One-Step Formation of Phi29 pRNA 3WJ from Three RNA Fragments
por: Binzel, Daniel W., et al.
Publicado: (2014)

Addition to Entropy-Driven One-Step Formation of Phi29 pRNA 3WJ from Three RNA Fragments
por: Binzel, Daniel W., et al.
Publicado: (2014)

Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas
por: Salmón, Marina, et al.
Publicado: (2023)

Determination of EGFR and KRAS mutational status in Greek non-small-cell lung cancer patients
por: PAPADOPOULOU, EIRINI, et al.
Publicado: (2015)

Rational design for controlled release of Dicer-substrate siRNA harbored in phi29 pRNA-based nanoparticles
por: Binzel, Daniel W., et al.
Publicado: (2021)

Radiochemical Synthesis of 4-[(18)F]FluorobenzylAzide and Its Conjugation with EGFR-Specific Aptamers
por: Il’in, Viktor A., et al.
Publicado: (2022)

Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer
por: Shin, Dong Hoon, et al.
Publicado: (2023)

Assessment and comparison of thermal stability of phosphorothioate-DNA, DNA, RNA, 2′-F RNA, and LNA in the context of Phi29 pRNA 3WJ
por: Piao, Xijun, et al.
Publicado: (2018)

Advancement of the Emerging Field of RNA Nanotechnology
por: Jasinski, Daniel, et al.
Publicado: (2017)

Anti-EGFR antibody conjugated silica nanoparticles as probes for lung cancer detection
por: Wan, Jun, et al.
Publicado: (2017)

Intratumor heterogeneity and tissue distribution of KRAS mutation in non-small cell lung cancer: implications for detection of mutated KRAS oncogene in exhaled breath condensate
por: Kordiak, Jacek, et al.
Publicado: (2018)

Fast and Selective Plasmonic Serotonin Detection with Aptamer-Gold Nanoparticle Conjugates
por: Chávez, Jorge L., et al.
Publicado: (2017)

Aptamer-Conjugated Superparamagnetic Ferroarabinogalactan Nanoparticles for Targeted Magnetodynamic Therapy of Cancer
por: Kolovskaya, Olga S., et al.
Publicado: (2020)

Aptamer–Target–Gold Nanoparticle Conjugates for the Quantification of Fumonisin B1
por: Mirón-Mérida, Vicente Antonio, et al.
Publicado: (2021)

EGFR, ALK, RET, KRAS and BRAF alterations in never-smokers with non-small cell lung cancer
por: DONG, YU, et al.
Publicado: (2016)

EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer
por: Tomasini, Pascale, et al.
Publicado: (2016)

Detection of EGFR and KRAS Mutation by Pyrosequencing Analysis in Cytologic Samples of Non-Small Cell Lung Cancer
por: Lee, Seung Eun, et al.
Publicado: (2016)

KRAS oncogene in lung cancer: focus on molecularly driven clinical trials
por: Kempf, Emmanuelle, et al.
Publicado: (2016)

Oncogenic mutation or overexpression of oncogenic KRAS or BRAF is not sufficient to confer oncogene addiction
por: Ito, Reina E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rapsiiveauqe5d1lnbcceuks71